Barely Significant
← all excerpts

Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.

Nat Commun · 2023 · PMC10516894 · PMID 37739939

Europe PMCDOI
1
hedged sentence
0.0350
closest p · 0.7× alpha
0.0350
boldest claim

The sentences

slightly significantp value = 0.035actually significant
By stratifying patients according to the ICR/GIE classification of week 12 biopsies we found a slightly significant difference ( p value = 0.035, log-rank test) in OS and in PFS ( p value = 0.022, log-rank test) between the High-ICR/GIE and the High-ICR/Non-GIE group (Fig. 6c and Supplementary Fig 9b ).

also in 1,762 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.